Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Tolerogenic Dendritic Cells in Type 1 Diabetes Mellitus
NCT05207995Phase 2Completed
- Start
- Mar 2022
- Primary completion
- Dec 2023
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous tolerogenic dendritic cells in type 1 diabetes mellitus (T1D) (2 arms). Primary endpoints: Glucose concentration in blood at 1 year, Glycated hemoglobin concentration at 1 year and 3 more. Started Mar 2022; status: completed.
02
Drugs
autologous tolerogenic dendritic cells
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05207995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05207995.